Collegium Pharmaceutical, Inc. (COLL) CTO Sells $68,493.00 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CTO Alison B. Fleming sold 4,029 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $17.00, for a total value of $68,493.00. Following the completion of the transaction, the chief technology officer now owns 28,513 shares in the company, valued at approximately $484,721. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Collegium Pharmaceutical, Inc. (NASDAQ COLL) traded up $0.98 during mid-day trading on Tuesday, reaching $18.58. 1,759,758 shares of the company’s stock were exchanged, compared to its average volume of 480,323. Collegium Pharmaceutical, Inc. has a 1-year low of $7.37 and a 1-year high of $19.21.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 110.99% and a negative return on equity of 55.48%. The business had revenue of $11.95 million for the quarter, compared to analysts’ expectations of $5.31 million. During the same quarter in the previous year, the firm posted ($1.13) EPS. The business’s revenue for the quarter was up 2814.6% compared to the same quarter last year. equities research analysts forecast that Collegium Pharmaceutical, Inc. will post -2.63 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/11/21/collegium-pharmaceutical-inc-coll-cto-sells-68493-00-in-stock.html.

A number of hedge funds have recently modified their holdings of the business. Sectoral Asset Management Inc raised its holdings in Collegium Pharmaceutical by 41.4% during the 2nd quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock valued at $22,627,000 after acquiring an additional 529,503 shares during the period. Macquarie Group Ltd. raised its holdings in Collegium Pharmaceutical by 18.9% during the 3rd quarter. Macquarie Group Ltd. now owns 1,329,979 shares of the specialty pharmaceutical company’s stock valued at $13,951,000 after acquiring an additional 211,288 shares during the period. Morgan Stanley raised its holdings in Collegium Pharmaceutical by 684.8% during the 1st quarter. Morgan Stanley now owns 885,268 shares of the specialty pharmaceutical company’s stock valued at $8,906,000 after acquiring an additional 772,464 shares during the period. Vanguard Group Inc. raised its holdings in Collegium Pharmaceutical by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock valued at $8,113,000 after acquiring an additional 58,398 shares during the period. Finally, Prudential Financial Inc. raised its holdings in Collegium Pharmaceutical by 62.8% during the 3rd quarter. Prudential Financial Inc. now owns 557,050 shares of the specialty pharmaceutical company’s stock valued at $5,843,000 after acquiring an additional 214,860 shares during the period. 77.23% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently commented on COLL. Piper Jaffray Companies reiterated a “buy” rating and issued a $14.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, September 8th. BidaskClub downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $19.33.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply